CARB-X
HHS, Wellcome Commit $370M in New Funding for CARB-X
Founded in 2016, CARB-X supports the advancement of therapeutics, vaccines, rapid diagnostics, and devices to treat drug-resistant bacterial infections.
Numerous technologies in development to help with the diagnosis of sepsis have a singular objective ─ detect the condition as quickly as possible.
CARB-X Awarding up to $578K to Accelerate Diagnostics for Fiber Optic Sepsis Testing Tech
CARB-X said its award will support the development of a compact instrument and research into the possible application of fiber optic technology to identify bacteria.
CARB-X Awards SpeeDx up to $3.7 Million for CT/NG Test on QuantumDx Q-POC
SpeeDx will develop a rapid, portable test for chlamydia and gonorrhea that can determine the latter's antimicrobial susceptibility, as well.
CARB-X Awards GenomeKey Up to $9.5M to Develop Rapid Diagnostic Test for Sepsis
GenomeKey's technology combines methods to separate bacterial and human DNA, next-generation sequencing, and machine learning.